We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00145691
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : March 21, 2007
Information provided by:

Study Description
Brief Summary:

We intend to conduct a phase III b trial to verify Oxcarbazepine's effect in agitation and aggression in patients with dementia. We designed the study as a randomized, double-blind, placebo-controlled multi center trial. Hundred patients will be included. The treatment period will be eight weeks, with a further follow up of four weeks.

The primary outcome measure will be the reduction in aggression and agitation as measured by means of NPI-NH-subscale agitation / aggression (Neuropsychiatric Inventory, Nursing Home Version). Secondary outcomes are reduction in aggression as measured by BARS (Behavior Agitation Rating Scale)and reduction in the burden to health-care personnel as measured by NPI-NH.

Condition or disease Intervention/treatment Phase
Agitation Aggression in Dementia Drug: Oxcarbazepine Phase 3

Detailed Description:

Inclusion criteria: Patients of either gender, 55 years of age or older, living in a nursing home diagnosed with or a strong suspicion of dementia of Alzheimer’s type or vascular origin, and BPSD in form of agitation / aggression as measured by subscale of NPI-NH and BARS.

Exclusion criteria: Patients that have any other kind of dementia as FTD, PD or LBD; patients with hepatic or renal failure, or diseases that make it impossible to follow the study schedule; patients on antiepileptics or antipsychotics.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study
Study Start Date : September 2005
Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Reduction in aggression and agitation as measured by means of NPI-NH-subscale agitation / aggression (Neuropsychiatric Inventory, Nursing Home Version)

Secondary Outcome Measures :
  1. Reduction in aggression as measured by BARS (Behavior Agitation Rating Scale),
  2. Reduction in the burden to health-care personnel as measured by NPI-NH.
  3. Evaluate the concomitant use of acute medication (haloperidol), and compare the frequency and dosage used in the two groups.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Alzheimer’s dementia, vascular dementia or mixed forms of both according to ICD10 (F00, F01) criteria.
  • The patient is 55 years of age or older.
  • Residents at a nursing home and who have been there for at least 4 weeks prior to inclusion.
  • Signed informed consent by the patient or the relatives signed agreement that they have no reservations against patient’s participation in the study.
  • At least one week history of agitation or aggression, score 6 or more in NPI-NH-subscale agitation/aggression.

Exclusion Criteria:

  • Previous intolerability or known hypersensitivity to Oxcarbazepine or its equivalents
  • Low sodium serum levels <135 mmol/L
  • Severe impaired renal function (creatinine clearance <30 ml/min, calculated with Cockroft + Gault’s formula)
  • Hepatic failure (transaminases (g-GT and ALAT > 3 times upper normal limit).
  • Patients with AV-block II and III and all kinds of arrhythmia necessitating a treatment.
  • Severe somatic diseases that afford a change of medication and will compromise the attendance to the study.
  • Patients on cyclosporine.
  • Patients in need of strong analgesics like opioids as codeines
  • Patients taking carisoprodol
  • Alcohol or drug abuse during the last 12 months (used a higher dosage than prescribed)
  • The patient has been on ChEIs or memantine for less than 3 months or any change in the dosage during the last 2 weeks.
  • The patient is taking antiepileptics or antipsychotics (may be included two weeks after the use of antipsychotics has been ended).
  • The patient is taking MAOI or lithium
  • The patient with a dementia of type PDD, FTD or DLB
  • The patients with a severe or acute neurological disease (e.g. epilepsy, acute CVE, severe Parkinson’s disease, acute confusion) or a severe psychiatric disorder like bipolar disorder, schizophrenia...
  • The patients who have participated in another clinical trial during the last 3 months.
  • The patients who have been randomized to the same study before.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00145691

Sykehuset Innlandet HF
Reinsvoll, Oppland, Norway, 2840
Sponsors and Collaborators
Sykehuset Innlandet HF
Principal Investigator: Oskar H Sommer, MD Sykehuset Innlandet HF
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00145691     History of Changes
Other Study ID Numbers: EudraCT number: 2004-005266-20
Sponsor’s Protocol Code: 1500
First Posted: September 5, 2005    Key Record Dates
Last Update Posted: March 21, 2007
Last Verified: March 2007

Additional relevant MeSH terms:
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Behavioral Symptoms
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic